The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma
NCT ID: NCT02002754
Last Updated: 2013-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
45 participants
INTERVENTIONAL
2012-06-30
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize:
A few of subjects with EB have some responses to Bambuterol Hydrochloride tablets therapy.
Most of subjects with CVA respond well to Bambuterol Hydrochloride tablets therapy
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
45 patients with chronic cough will be collected and two groups will formed based on diagnosis as follows:
Group 1: EB group The patients with eosinophilic bronchitis received Bambuterol Hydrochloride tablets 10mg Q24 for three days .
Group 2: CVA group The patients with cough variant asthma received Bambuterol Hydrochloride tablets 10mg Q24 for three days .
Observe the response to Bambuterol Hydrochloride tablets treatment three days later and compare the effective rate of patients with EB and CVA. Then the study will be over.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eosinophilic bronchitis
Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
Bambuterol Hydrochloride tablets
Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
cough variant asthma
Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
Bambuterol Hydrochloride tablets
Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bambuterol Hydrochloride tablets
Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients whose chest x-ray outcome was normal or without any active focus.
3. Patients with eosinophilic bronchitis who were diagnosed with the result of sputum eosinophil percentage (Eos%) over 2.5%, and the negative result in bronchial provocation test by methacholine inhalation challenge.
4. Patients with cough variant asthma have positive result in bronchial provocation test.
5. Patients who was aged from 18 years old (≥ 18 years old ) to 75 years old (≤ 75 years old).
Exclusion Criteria
2. Patients with concomitance of GERC (gastroesophageal reflux-related chronic cough), chronic bronchitis , bronchiectasis, bronchial tuberculosis, ACEI induced cough, bronchogenic carcinoma, psychologic cough, pulmonary fibrosis, bronchus foreign body, microlithiasis, tracheobroncheopathia osteochondroplastica, mediastinal tumor, left ventricular dysfunction.
3. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study.
4. Subjects who are diagnosed with past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease. e.g.nasal-sinus infection, lower respiratory tract infection, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis or bronchopulmonary dysplasia.
5. Subjects who demonstrate significant abnormality on biochemistry, hematology, ECG.
6. Patients who does not cooperate with us.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Guangzhou Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kefang Lai
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou Institute of Respiratory Disease
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kefang Lai, PHD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
cough2009
Identifier Type: -
Identifier Source: org_study_id